Dr. Klencke is a seasoned executive with more than 20 years of experience across both pharmaceutical and biotech companies. She most recently served as the Chief Medical and Chief Development Officer of Sierra Oncology Inc., which was acquired by GlaxoSmithKline in 2022. Dr. Klencke has served as an independent board member of eFFECTOR Therapeutics, Inc. since 2021, Immune-Onc Therapeutics, Inc. since 2022, and Lexent Bio, Inc. from 2017 until the company’s acquisition by Foundation Medicine, Inc. in 2020. From 2011 to 2015, Dr. Klencke served as Senior Vice President, Global Development at Onyx Pharmaceuticals Inc., which was acquired by Amgen Inc. in 2013. She also led a variety of both early- and late-stage oncology programs during her tenure at Genentech, Inc. from 2003 to 2011. Throughout her career, she has played a major role in the successful development, approval and early commercialization of a number of important oncology products. Dr. Klencke completed her Internal Medicine and Hematology and Oncology training at the University of California, San Francisco and remained there as an Assistant Professor of Medicine in Oncology, focusing on clinical research, from 1995 to 2002. She holds a Bachelor of Science from Indiana University and a Doctor of Medicine from the University of California, Davis.